Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06221800 · ClinicalTrials.gov registry record
Assess Diversity of Gut Microbiome in Met NSCLC in Correlation to Tx & Adverse Effects
A clinical trial of Non-Small Cell Lung Cancer, sponsored by University of California, Irvine.
- Recruiting
- Registry status
- 82
- Enrollment target
- 1
- Study location
NCT06221800: Recruiting study of Non-Small Cell Lung Cancer, sponsored by University of California, Irvine.
NCT06221800 is a study of Non-Small Cell Lung Cancer that is actively recruiting participants, run by University of California, Irvine. The registered enrollment target is 82 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06221800, a study of Non-Small Cell Lung Cancer, is actively recruiting participants, sponsored by University of California, Irvine.
- RECRUITING
- Registry status
- 82 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a pilot study collecting data on the diversity and composition of gut microbiomes in subjects with advanced/metastatic Non-Small Cell Lung Cancer (NSCLC) while receiving treatment for NSCLC.
Primary Outcome
To summarize the diversity and composition of gut microbiomes at baseline or prior to initiation of therapy
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Microbiome
Study Locations (1)
California
- Chao Family Comprehensive Cancer Center University of California, Irvine - Orange
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2024-01-31 |
| Est. Completion | 2026-12 |
What NCT06221800 shows while recruiting
NCT06221800 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 82 participants, a relatively small participant target, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Microbiome is the first listed.
NCT06221800 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06221800 about?
NCT06221800 is a clinical study titled "Assess Diversity of Gut Microbiome in Met NSCLC in Correlation to Tx & Adverse Effects". This is a pilot study collecting data on the diversity and composition of gut microbiomes in subjects with advanced/metastatic Non-Small Cell Lung Cancer (NSCLC) while receiving treatment for NSCLC.
What is the current status of trial NCT06221800?
This trial is currently recruiting. The enrollment target is 82 participants. The study started on 2024-01-31. Estimated completion is 2026-12.
What conditions does trial NCT06221800 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT06221800?
The interventions under investigation include: Microbiome (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06221800?
This trial is sponsored by University of California, Irvine, which has 368 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06221800 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06221800's enrollment target sits among peer trials
82 267th of 454 higher than 187 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03319901 · 82 participants · Phase 1
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
- NCT03493425 · 82 participants · Phase 2
Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery
- NCT04105270 · 82 participants · Phase 2
RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial
- NCT04428658 · 82 participants · NA
Randomized Trial of Supplemental Synchronous and Asynchronous Telehealth to Improve Glycemic Control for Pediatric Patients With Type 1 Diabetes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI